Results 71 to 80 of about 80,266 (330)

BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis

Nature Communications
Neuroinflammation in the central nervous system (CNS), driven largely by resident phagocytes, has been proposed as a significant contributor to disability accumulation in multiple sclerosis (MS) but has not been addressed therapeutically.
Ross Gruber, Gregory S Wirak, Anna S Blazier, Lan Lee, M. Dufault, Nellwyn Hagan, Nathalie Chretien, Michael LaMorte, Timothy R Hammond, Agnes Cheong, Sean K. Ryan, Andrew Macklin, Mindy Zhang, Nilesh Pande, E. Havari, Timothy J. Turner, Anthony Chomyk, Emilie Christie, Bruce D. Trapp, D. Ofengeim   +19 more
semanticscholar   +1 more source

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

Frontiers in Pharmacology, 2022
Despite recent improvements in multiple myeloma (MM) treatment, MM remains an incurable disease and most patients experience a relapse. The major reason for myeloma recurrence is the persistent stem cell-like population.
Weam Othman Elbezanti, Weam Othman Elbezanti, Omar S. Al-Odat, Omar S. Al-Odat, Robert Chitren, Robert Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey   +14 more
doaj   +1 more source

Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia

Leukemia
Targeting BTK has profoundly changed the face of CLL treatment over the past decade. Iterative advances in the cat and mouse game of resistance and redesign have moved BTK inhibitors from covalent to non-covalent and now targeted protein degraders ...
Richard L. Wong, Michael Y. Choi, Huan-You Wang, T. Kipps   +3 more
semanticscholar   +1 more source

Platelet Rubicon Bidirectional Regulation of GPVI and Integrin αIIbβ3 Signaling Mitigates Stroke Infarction Without Compromising Hemostasis

Advanced Science, EarlyView.
This study identifies Rubicon as a key platelet protein that bidirectionally regulates GPVI and integrin αIIbβ3 signaling. Platelet Rubicon protects against cerebral ischemia‐reperfusion injury by limiting infarction without increasing hemorrhage.
Xiaoyan Chen, Jingke Li, Yangyang Liu, Li Li, Xin Deng, Yilin Sheng, Xianyu Zhu, Xiao Jiang, Wei Li, Xueli Cai, Qiming Sun, Hu Hu   +11 more
wiley   +1 more source

The tyrosine kinase Btk regulates the macrophage response to Listeria monocytogenes infection.

PLoS ONE, 2013
In this study we investigated the role of Bruton's tyrosine kinase (Btk) in the immune response to the Gram-positive intracellular bacterium Listeria monocytogenes (Lm).
Afitap Derya Köprülü, Renate Kastner, Sebastian Wienerroither, Caroline Lassnig, Eva Maria Putz, Eva Maria Putz, Olivia Majer, Benjamin Reutterer, Veronika Sexl, Karl Kuchler, Mathias Müller, Thomas Decker, Wilfried Ellmeier   +12 more
doaj   +1 more source

Inactivating BTK mutations in large B‐cell lymphoma in a real‐world cohort: Strong correlation with BCL2 translocation

eJHaem, 2022
Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor‐treatment naïve patients.
Lone Schejbel, Marie Fredslund Breinholt, Anne Ortved Gang, Torsten Holm Nielsen, Lars Møller Pedersen, Estrid Høgdall, Peter Nørgaard   +6 more
doaj   +1 more source

BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair

Acta Neuropathologica
In multiple sclerosis (MS), persisting disability can occur independent of relapse activity or development of new central nervous system (CNS) inflammatory lesions, termed chronic progression.
Anastasia Geladaris, Sebastian Torke, Darius Saberi, Y. B. Alankus, Frank Streit, Sabrina Zechel, Christine Stadelmann-Nessler, Andreas Fischer, U. Boschert, Darius Häusler, Martin S. Weber   +10 more
semanticscholar   +1 more source

BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining

Frontiers in Oncology, 2020
Tumor microenvironment (TME) plays a crucial role in the initiation and progression of lung adenocarcinoma (LUAD); however, there is still a challenge in understanding the dynamic modulation of the immune and stromal components in TME.
K. Bi, Xu-Ge Wei, Xiao-Xue Qin, Bo I Li
semanticscholar   +1 more source

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy

Haematologica, 2022
Strategies to overcome resistance to FMS-like tyrosine kinase 3 (FLT3)-targeted therapy in acute myeloid leukemia (AML) are urgently needed.
Weiguo Zhang, Guopan Yu, Hongying Zhang, Mahesh Basyal, Charlie Ly, Bin Yuan, V. Ruvolo, Sujan Piya, Seemana Bhattacharya, Qi Zhang, G. Borthakur, V. Battula, M. Konopleva, William Q. Rice, M. Andreeff   +14 more
semanticscholar   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source